Pilot study explores testosterone pulses for resistant prostate cancer
NCT ID NCT03734653
First seen Nov 06, 2025 · Last updated May 19, 2026 · Updated 25 times
Summary
This early-phase study tested whether giving testosterone skin patches in cycles with the drug enzalutamide is possible and safe for men with castration-resistant prostate cancer. Thirty men on standard hormone therapy participated. The goal was to see if at least half of eligible patients would join and stay in the study, and to track any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Colorado Hospital
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.